Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

This perspective discusses Villani et al.'s findings on the role of the IGF regulatory protein Igfbp2 in basal cell carcinogenesis and highlights potential therapeutic and preventive targets, while raising questions about the cell of origin.

In this study, the disruption of Gh/tissue transglutaminase in mice did not affect viability but reduced thymocyte viability and fibroblast adhesion, suggesting its role in cell stabilization and extracellular matrix interactions.

In this study, two unrelated Honduran patients with Sjögren-Larsson syndrome had the same genetic mutation but displayed different disease severities, suggesting that factors beyond the ALDH3A2 mutation influence clinical outcome.

This study presents a new, effective method for delivering dental epithelial stem cells to the jaw, aiming to advance therapies for enamel defects and regeneration.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

This article briefly notes the benefits of global collaboration among hair restoration societies but reports no new findings or research results.

This study suggests that fractional infrared technology may effectively improve cervical skin laxity by enhancing dermal thickness without adverse effects in a small pilot group.

This study used Cisd2 knockout mice models and found that these mice display premature aging characteristics and an increase in dysfunctional neutrophils, suggesting Cisd2's role in calcium homeostasis and neutrophil function via interactions with Calnexin and SERCA.

This study found significant improvements in hair growth parameters and a reduction in hair fall after using the test product for 90 days, with no adverse events reported.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

This correspondence is an invitation to the 18th Annual Scientific Meeting of the International Society of Hair Restoration Surgery, with no research results presented.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

In this study, researchers observed distinct morphological differences in hair follicles of mutant mouse genotypes, influenced by the expression levels of keratin2-6g, which is essential for proper hair follicle development.

This study identifies iRhom2 as a crucial regulator of hair follicle differentiation, showing that the iRhom2Uncv mutation leads to dysplasia and reduced TACE maturation, resulting in a hairless phenotype in mice.

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

This study reports a unique case of coinheritance of BRCA2 and CYLD pathogenic variants in a man with metastatic malignant cylindroma, suggesting that recognizing such genetic profiles in rare conditions can provide new treatment options, including the potential use of therapies targeting BRCA deficiency.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This case study describes a 7-month-old boy diagnosed with keratitis-ichthyosis-deafness syndrome due to a de novo GJB2 gene mutation, highlighting the challenges in treatment and eventual fatal outcome due to severe complications.

This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.

This study analyzed screening data from 218 alopecia areata patients before starting Janus kinase inhibitors, revealing the importance of pre-treatment screening due to risks of infections like tuberculosis and hepatitis B, with 74.8% of patients proceeding to treatment in real-world settings.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.